Physician profile
Michael E Contreras
NPI 1457367013
$8,424.17
in general payments reported to CMS, 2019-2025
28 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $650 · 2021: $1,138 · 2022: $1,458 · 2023: $1,272 · 2024: $2,109 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,304 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,303.69 |
| Education | $169.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,164.51 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $820.78 | 2019-2025 | Skyrizi |
| Arcutis Biotherapeutics, INC. | $797.05 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $665.32 | 2020-2025 | Aklief, Dysport |
| Genzyme Corporation | $650.28 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $497.51 | 2020-2025 | Ilumya |
| Epi Health, LLC | $436.57 | 2019-2022 | |
| Leo Pharma INC. | $428.39 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $359.94 | 2020-2021 | |
| Dermavant Sciences, INC. | $354.63 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $328.99 | 2019-2025 | Dupixent, Libtayo |
| Journey Medical Corporation | $316.47 | 2021-2025 | |
| Pfizer INC. | $292.57 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $217.17 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $208.15 | 2019-2024 | Jublia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $187.65 | 2021-2024 | Opzelura |
| Amgen INC. | $151.57 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $135.46 | 2022-2024 | Sotyktu |
| Stemline Therapeutics INC. | $86.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Biofrontera INC. | $67.90 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Biotech, INC. | $57.00 | 2021-2024 | Tremfya |
| Almirall LLC | $39.31 | 2019-2025 | Seysara |
| Novocure INC. | $25.86 | 2024 | Optune |
| Celgene Corporation | $16.94 | 2019 | |
| Lilly USA, LLC | $13.96 | 2023 | Taltz, Olumiant |
| Merck Sharp & Dohme LLC | $13.68 | 2019 | |
| Organon LLC | $10.47 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Contreras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.